Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Acute Myeloid Leukemia

Experts Share Recommendations on Managing Cancer During COVID-19 Pandemic

Conor Killmurray

The COVID-19 pandemic will continue to alter how patients with cancer receive their treatment, and experts within the United States who saw the virus strike early are offering their advice to other hospitals just starting to feel the effects.

Immunotherapy Combination Offers Hope to Patients with Relapsed/Refractory AML

Katie Kosko

Patients with acute myeloid leukemia whose disease has relapsed or become resistant to treatment saw a benefit with a combination of Opdivo and Vidaza.

Immunotherapy After Transplant Improves Outcomes in Acute Myeloid Leukemia

Jessica Skarzynski

Patients with acute myeloid leukemia often have to undergo transplant during treatment but are susceptible to other side effects, but new research indicates that the use of immunotherapy after thee treatments can improve patient outcomes.

CURE New Issue Alert: 2020 Hematology Special Edition-1

Jessica Skarzynski

Here are the latest highlights from the first CURE Hematology Special Edition issue for 2020.

Remission Drives Ambition: Experts Look to New Methods in AML Treatment

Debu Tripathy, M.D.

Targeted therapies have changed the landscape of cancer care, and now, hope for remission is a possibility for certain patients with acute myeloid leukemia with new approved therapies.

Extending the Options for Patients with AML by Making It Personal

A wave of new targeted therapies expands the options in acute myeloid leukemia.

Novel Combination May Address Unmet Need in Relapsed or Refractory Acute Myeloid Leukemia

Ryan McDonald

Treatment options for patients with acute myeloid leukemia are limited, especially for older patients, but a new trial looking at novel therapy combinations could change the treatment landscape.

Mutations in Donor Stem Cells Could Harm the Health of Patients with Cancer, Study Finds

Katie Kosko

Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.

MDM2 Inhibitor Shows Promise For Patients With AML

Naval Daver, MD

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

Genomic Sequencing Could Individualize Diagnosis, Treatment of Myeloid Cancers

Beth Fand Incollingo

Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.

Acute Myeloid Leukemia

Sign In